News headlines about Novartis (NYSE:NVS) have trended positive on Wednesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Novartis earned a media sentiment score of 0.35 on Accern’s scale. Accern also gave news stories about the company an impact score of 49.4942377653097 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern’s rankings:
- Novartis becomes latest big-name collaborator for Chapel Hill company (finance.yahoo.com)
- Ignyta and Its Key Risks in 2018 (finance.yahoo.com)
- Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar (finance.yahoo.com)
- Novartis AG (NVS) to Post FY2022 Earnings of $8.24 Per Share, Jefferies Group Forecasts (americanbankingnews.com)
- Novartis AG (NVS) Sees Large Decrease in Short Interest (americanbankingnews.com)
Novartis (NYSE:NVS) traded down $0.51 during mid-day trading on Wednesday, hitting $85.86. 796,682 shares of the company traded hands, compared to its average volume of 1,001,471. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. The firm has a market capitalization of $225,980.00, a PE ratio of 30.56, a P/E/G ratio of 2.55 and a beta of 0.74. Novartis has a twelve month low of $69.53 and a twelve month high of $86.90.
Several research analysts have commented on NVS shares. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 target price for the company in a report on Tuesday, September 19th. Leerink Swann raised their target price on shares of Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, September 26th. Finally, Nord/LB reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Five equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. Novartis currently has a consensus rating of “Hold” and a consensus price target of $85.32.
TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.com-unik.info/2018/01/10/positive-press-coverage-somewhat-unlikely-to-impact-novartis-nvs-share-price.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.